bioAffinity Technologies annual net debt
2021
2022
2023
2024
2025
bioAffinity Technologies Net Debt Growth & History (BIAF)
bioAffinity Technologies's net debt was −$5.4M for fiscal 2025.
View full bioAffinity Technologies company overviewbioAffinity Technologies annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$5.4M | −$5.6M | — |
| 2024 | 2024-12-31 | $204,054 | $1.4M | — |
| 2023 | 2023-12-31 | −$1.2M | $9.9M | — |
| 2022 | 2022-12-31 | −$11.2M | −$21.0M | — |
| 2021 | 2021-12-31 | $9.8M | — | — |
bioAffinity Technologies quarterly net debt
Q4.21
Q3.22
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$1.1M | −$842,004 | — |
| Q1 2026 | 2026-03-31 | −$1.8M | −$2.5M | — |
| Q4 2025 | 2025-12-31 | −$5.4M | −$5.6M | — |
| Q3 2025 | 2025-09-30 | −$6.9M | −$7.7M | — |
| Q2 2025 | 2025-06-30 | −$211,736 | −$763,557 | — |
| Q1 2025 | 2025-03-31 | $733,534 | $1.7M | — |
| Q4 2024 | 2024-12-31 | $204,054 | $1.4M | — |
| Q3 2024 | 2024-09-30 | $801,556 | $3.6M | — |
| Q2 2024 | 2024-06-30 | $551,821 | — | — |
| Q1 2024 | 2024-03-31 | −$986,159 | — | — |
| Q4 2023 | 2023-12-31 | −$1.2M | — | — |
| Q3 2023 | 2023-09-30 | −$2.8M | $10.3M | — |
| Q3 2022 | 2022-09-30 | −$13.2M | — | — |
| Q4 2021 | 2021-12-31 | $9.8M | — | — |
bioAffinity Technologies net debt trends
Between the periods ended 2021-12-31 and 2025-12-31, bioAffinity Technologies's net debt decreased from $9.8M to −$5.4M, a change of −$15.2M. The latest reported quarter, Q2 2026, shows −$1.1M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review bioAffinity Technologies source filings ↗